Lei Xu1,2, Xueying Mao1, Alistair Grey3,4, Glenda Scandura1, Tianyu Guo1, Edwina Burke1, Jacek Marzec1, Semah Abdu1, Elzbieta Stankiewicz1, Caitlin R Davies1, Prabhakar Rajan1,3,4,5, Karen Tipples3, John Hines3,5, Pui Ying Chan6, Diane Campbell3, Karen Wilkinson3,5, Sakunthala Kudahetti1, Jonathan Shamash6, Tim Oliver1, Daniel Berney1, Greg Shaw3,4,5, Yong-Jie Lu1,7*
1Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
2Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
3Department of Urology, Barts Health NHS, London, UK.
4Division of Surgery and Interventional Sciences, University College London, London, UK
5Department of Urology, University College London NHS Foundation Trust, London, UK
6Department of Medical Oncology, Barts Health NHS, London, UK.
7First Affiliated Hospital & Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China